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Renal function in autologous hematopoietic cell support for breast
cancer. Autologous and allogeneic bone marrow grafting both require
cytoreductive therapy but only the allogeneic procedure requires immu-
nosuppressive agents. Allogeneic bone marrow transplantation has been
reported to be associated with a high incidence of both renal failure and
veno-occlusive disease (VOD) of the liver, the combination of which is
associated with a high morbidity and mortality. There is less known about
the frequency and severity of these complications in patients undergoing
autologous bone marrow transplantation. In the present study renal,
hepatic and other complications were examined in 232 patients with
Stages Il/Ill and IV breast cancer who were treated with high-dose
chemotherapy and autologous hematopoietic cell support with either
marrow or peripheral blood progenitor cells. The post-treatment severity
of the renal dysfunction was classified as follows: Grade 0, normal renal
function [< 25% decrement in glomerular filtration rate (GFR)]; Grade 1,
mild renal dysfunction (> 25% decrement in GFR but < a twofold
increase in serum creatinine); Grade 2, > twofold rise in serum creatinine
but no need for dialysis; Grade 3, > than twofold rise in serum creatinine
and need for dialysis. There were 102 patients (44%) who were classified
as Grade 0 and 81 patients (35%) who were classified as Grade 1 renal
dysfunction. Severe renal dysfunction (Grades 2 and 3) was observed in 49
of the 232 patients (21%). This severe renal dysfunction of 21% compares
with a previously reported 53% incidence of severe renal dysfunction for
allogeneic bone marrow transplantation. Similarly, the frequency of
hepatic VOD was less (4.7% or 11 of 232 patients) in this autologous bone
marrow transplant study as compared to a reported incidence of hepatic
VOD ranging from 22 to 53% in large series of allogeneic bone marrow
transplant patients. The severe renal dysfunction (Grades 2 and 3) in the
present autologous hematopoietic cell support study correlated most
significantly with sepsis, liver and pulmonary dysfunction. The major fall in
GFR occurred during chemotherapy but before hematopoietic cell sup-
port, thus primarily incriminating the cytoreductive therapy rather than
the hematopoietic cell support. The only significant effect of different
chemotherapy protocols was, at four weeks, the Taxol-treated group had
a significantly lower creatinine clearance as compared to the BCNU
treated group.
Breast cancer is the second leading cause of cancer death in
women in the United States. Recently, high dose chemotherapy
with autologous hematopoietic cell support has been increasingly
used in the treatment of patients with positive nodes and ad-
vanced metastatic breast cancer [1, 2]. During the three week
period required for hematopoietic reconstitution, complications
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are frequent and include infections, bleeding and organ toxicities
related to the chemotherapy [3, 4]; mortality rates varying from 3
to 55% have been reported during the first 100 days post
allogeneic and autologous bone marrow transplantation [5].
Acute renal failure is a common complication associated with
allogeneic bone marrow transplantation, occurring in more than
40% of patients; the clinical picture corresponds to that of
hepatorenal syndrome in more than 90% of these cases [6]. In
contrast, the effect of autologous hematopoietic cell support on
renal function has been less well examined than the effect of
allogeneic marrow transplantation [71. We have therefore evalu-
ated renal function in 232 women treated with high dose chemo-
therapy and autologous hematopoietic cell support for high risk
primary or metastatic breast cancer in the Bone Marrow Trans-
plant Unit of the University of Colorado Health Sciences Center.
Methods
Patient selection
The 232 patients described in this report are derived from a
series of 253 consecutive patients receiving high dose chemother-
apy and autologous hematopoietic cell support (that is, either
marrow or progenitor cells) for the treatment of stage Il/Ill and
stage IV breast cancer in the Bone Marrow Transplant Program
of the University of Colorado from September 1991 to August
1994. Twenty-one patients were excluded because of an absence
of renal function data in 10 patients, 9 patients who were treated
with monoclonal antibodies and different cytoreductive protocols,
and 2 males. A review of computerized medical records including
information on age, sex, baseline weight, stage of the cancer,
duration of the disease, high-dose chemotherapy regimen before
transplantation, renal, liver and pulmonary functions were under-
taken. An initial evaluation included history, physical exam,
histopathologic analyses, chest x-ray, pulmonary function tests,
electrocardiogram, cardiac nucleotide-gated blood pool scanning
(MUGA), body scan, and creatinine clearance. Patients were
required to have acceptable renal (creatinine clearance > 60
mI/mm), hepatic (SGOT, SGPT, bilirubin, and alkaline phos-
phatase < 1.5 times normal), pulmonary (DCLO > 60% predict-
ed), cardiac function (MUGA scan showing a left ventricular
ejection at rest > 50%) and negative virology for hepatitis C or B
and human immunodeficiency virus (HIV) prior to treatment with
high dose chemotherapy. The accepted patients generally re-
ceived outpatient induction therapy with adriamycin, fluorouracil
(SFU), and methotrexate prior to transplantation. All patients
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Table 1. Chemotherapy and stages of breast cancer
Chemotherapy Doses Stages
CPA/cDDP/BCNU CPA (1875 mg/rn2) Stages Il/Ill: (72 patients)
(Regular) eDDP (55 mg/rn2) Stage IV: (99 patients)
BCNU (450—600 mg/rn2)
Taxol/CPA/cDDP Taxol (135—825 mg/rn2) Stage IV: (30 patients)
cDDP (55 mg/rn2)
CPA (1875 mg/rn2)
CPA/cDDP/BCNU CPA (1875—3240 mg/rn2) Stage IV: (31 patients)
(Mesna) eDDP (55 mg/rn2)
BCNU (600-864 mg/rn2)
Mesna (5000 mg/rn2)
__________________
were treated on protocols approved by the University of Colorado
Health Sciences Center Institutional Review Board and all sub-
jects signed approved informed consent documents prior to
treatment.
Hematopoietic cell harvest and storage of bone marrow or
progenitor cells
The patient's hematopoietic cells were collected from the bone
marrow after repeated aspiration under regional or general
anesthesia from the posterior iliac crests and/or after collection of
blood progenitor cells by cytopheresis and then were frozen at
—196°C in 50 ml volume with 10% DMSO. Of the 232 patients
marrow was administered to 35 and peripheral blood progenitor
cells to 197 patients. For simplicity, the term hematopoietic cell
support will be used for either marrow or peripheral blood
progenitor cell support.
Chemotherapy protocols and stages of breast cancer
The chemotherapy protocols are shown in Table 1. Patients
were admitted seven days (day —7) before the bone marrow or
progenitor cells were reinfused (day 0). All patients had vascular
access with a double lumen dialysis catheter inserted prior to the
admission. In the phase II trials the regular high dose chemother-
apy (HDC) was undertaken as previously described [4] with
cisplatin (cDDP, 55 mg/rn2 as a 24 hr infusion for three days),
cyclophosphamide (CPA, 1875 mg/rn2 in 1 hr infusion) on day —6
through day —4 prior to hematopoietic cell reinfusion; the next
day carmustine was administered (BCNU, 450 or 600 mg/rn2 at a
rate of 5 mg/m2/min for 1 day). Hypotension during the BCNU
infusion was treated with a rapid infusion of saline or intravenous
phenylephrine. In the phase I trials, the mesna protocol was
designated to determine the maximally tolerated doses of CPA,
cDDP and BCNU using mesna (sodium mercaptoethane sulfo-
nate) in an attempt to minimize or prevent toxicity. In these phase
I trials, most patients received CPA in a dose varying from 1875 to
3240 mg/m2/day, cDDP in a dose of 55 mg/rn2/day infused over
three days prior to marrow reinfusion and BCNU in the dose of
600 to 864 mg/rn2 on day —3. Mesna was given as a continuous
infusion at 5000 mg/m2/day beginning before chemotherapy initi-
ation and concluding eight hours after completion of the chemo-
therapy. The protocol with Taxol/CPA/cDDP was designated as a
phase I trial with a 24 hour infusion of escalating doses of Taxol
seven days prior to bone marrow infusion, which was then
followed by cisplatin (55 mg/m2/day for 3 days) and CPA (1875
mg/m2/day for 3 days). The dose of Taxol varied from 135 to 825
mg/rn2 by protocol. The maximal tolerated dose was 775 mg/rn2.
Hydration with dextrose 5% and normal saline with added
potassium chloride (20 mEq/liter) at a rate of 250 ml/m2/hr was
started at least 12 hours prior to beginning chemotherapy and
infused continuously on day —7 through day —4 until four hours
after the completion of cisplatin. A urine flow rate of> 250 mI/hr
was required at all times during chemotherapy. In all patients
hourly replacement was undertaken of any deficit with 0.9%
normal saline and electrolytes including magnesium, potassium
and calcium. Bladder irrigation at a flow rate of one liter/hr was
begun prior to CPA and continued until after the eisplatin
infusion was completed. The vehicle used during the cisplatin
infusion was normal saline given at a rate of 42 ml/hr over 72
hours; Taxol was reconstituted with dextrose water/Chremophor
and infused at 84 mI/hr over 24 hours.
All patients received RBC transfusions to maintain an hemat-
ocrit of >28%. This averaged 4 to 5 units during the entire
hospital stay. Granulocyte colony stimulating factor (G-CSF) was
administered at the dose of 10 pg/kg daily as a 30 minute infusion
beginning the day of the marrow or peripheral blood progenitor
cell reinfusion (day 0) until the granulocyte count was > 5000/jd
for three consecutive days.
The antiemetic regimen before or during infusion of antineo-
plastic drugs consisted of diphenhydramine, prochiorperazine
(Compazine) and lorazepam (Ativan). These medications were
continued at least 48 hours after administration of all antineo-
plastic agents. Dexamethasone and cimetidine were administered
prior to Taxol to decrease allergic reactions.
All patients received empirical antibiotic therapy with broad
spectrum, intravenous antibiotics when the absolute granulocyte
count was < 500/pA and the patient had a fever greater than
38.3°C. The initial coverage included gentamicin 2.5 mg/kg then
1.5 mg/kg intravenously every eight hours, piperacillin 3 g every
four hours and vancomycin I g every 12 hours. If the fever
persisted more than 48 hours patients were enrolled in a random-
ized trial comparing amphotericin B versus fluconazole. Ampho-
tericin B was administered daily as a four hour infusion at a rate
of 0.6 mg/kg and fluconazole at the dose of 5 mg/kg adapted to the
creatinine clearance.
Patient monitoring and functional studies
Blood studies and urine analysis were performed systematically
at admission for a baseline evaluation and during the hospital
course. Toxicities were graded using the Southwest Oncology
Group (SWOG) classification. Complications including sepsis
(documented by positive blood cultures), hypotension (systolic
90 mm Hg) and cardiac output evaluation with a Swan Ganz
catheter (when required) were reported along with organ system
toxicities such as peripheral neuropathy, pulmonary and hepatic
toxicities. As earlier defined [6], veno-occlusive disease (VOD) of
the liver was considered when two of three clinical criteria were
found including: (a) jaundice, (h) hepatomegaly or right upper
quadrant pain, (c) ascites or unexplained weight gain within 14
days after marrow infusion, without other causes of hepatic
dysfunction. Hepatic toxicity was defined by abnormal liver func-
tion tests (values> 1.5 times normal). Hepatorenal syndrome was
based on renal dysfunction in the presence of a urine sodium
concentration < 10 mEq/liter and a urine/plasma urea ratio > 20,
which did not reverse with saline infusion, Diagnosis of pulmonary
toxicity was based on: a > 25% decrease in the single breath
carbon monoxide diffusing capacity (DLCO) when compared to
1028 Merouani et al: Renal function and breast cancer
pretreatment testing; a lung biopsy showing histologic changes
typical of acute lung injury; or new onset of shortness of breath
and oxygen desaturation with moderate exercise when pulmonary
edema, infection, or metastatic tumor had been excluded.
The renal function was assessed by the serum creatinine
concentration and a fall in calculated clearance of creatinine with
the Cockcroft and Gault formula [8] in the 232 patients before
chemotherapy (day —7), before hematopoietic cell support (day
—1) and post-hematopoietic support (days 7, 14, 21, and 3
months). As recommended for women [8], the values were
multiplied by 0.85 for the 232 women. In 85 patients, there was a
highly significant correlation between the creatinine clearances
calculated by the Cockcroft and Gault formula and those mea-
sured by 24-hour urine collections (P < 0.001).
Renal dysfunction was classified arbitrarily using the determi-
nation of glomerular filtration rate (GFR) with the calculated
creatinine clearance. Grade 0, or normal renal function, corre-
sponded to a decrement in creatinine clearance of less than 25%
from the baseline values. Grade 1 renal dysfunction corresponded
to a rise in the serum creatinine that was less than twofold from
the baseline value and a fall in the GFR that was more than 25%
from the baseline value. Grade 2 and Grade 3 renal dysfunction
corresponded to a rise in the serum creatinine greater than
twofold above the baseline values and a fall of GFR of more than
25% from the baseline value without dialysis in Grade 2, and with
dialysis in Grade 3.
Statistical methods
Continuous variables are expressed as mean standard error.
For dichomotomous variables the frequency of positive occur-
rences are given along with their corresponding percentages.
Comparisons of continuous variables between the various group-
ings of renal dysfunction were facilitated by using either paired or
unpaired Student's t-tests as appropriate, or an analysis of vari-
ance (ANOVA). Associations between the latter groupings and
dichotomous variables were examined using chi-square tests, or
Fisher's exact test where appropriate. The relative contributions
of continuous and dichotomous variables on the outcome of grade
of renal dysfunction were examined using stepwise multiple
logistic regression. SAS statistical software was used for all
analyses.
Results
Patient baseline characteristics
The therapeutic regimens based on stage of breast cancer are
shown in Table 1. There were no differences in age (45.5 0.8 vs.
44.9 0.5 years), body wt (67.3 1.7 vs. 66.9 1.0 kg), baseline
renal function (serum creatinine 0.85 0.01 vs. 0.84 0.03
mg/dl), hematological parameters, plasma albumin and electro-
lytes, liver and pulmonary function tests (data not shown) between
those patients with stage Il/Ill (72 patients) versus stage IV [160]
patients) breast cancer, An exception was statistically significant
but clinically insignificant difference in plasma calcium (9.0 0.1
vs. 8.6 0,1 mg/dl).
Changes in blood chemistries after chemotherapy
After treatment with chemotherapy a profound neutropenia
occurred in all patients and the mean white blood cell count fell
from 14,600 1,060 mm3 before chemotherapy to 2,860
2 10/mm3 on day —1 and 580 90/mm3 on day 7 post-hemato-
poietic cell infusion. Evidence of hematopoietic recovery occurred
between day 7 and day 14 post-hematopoietic cell infusion, with a
mean 7,400 790/mm3 white blood count on day 14. The
duration of the neutropenic period was generally two to three days
shorter in the patients reinfused with peripheral blood progenitor
cells rather than marrow. The platelet count decreased from a
mean baseline value of 160,800 5,100 mm3 to 35,050
1,300/mm3 on day 7 and remained low until day 21 post-hemato-
poietic cell infusion, with a value of 43,700 5,700/mm3. Hemat-
ocrit and hemoglobin fell from 41.3 0.24 to 34 0.3% and from
14.03 0.08 to 11.8 0.1 g/dl, respectively, from the baseline
value during the hospital course.
After hydration during chemotherapy there was a slight but
statistically significant decrease (all P < 0.001) from the baseline
plasma values for sodium (139 0.15 to 133.9 0.2 mm/liter),
potassium (3.85 0.01 to 3.73 0.02 mEq/liter), chloride
(107.1 0.3 to 104.5 0.3 mEq/liter), total proteins (6.1 0.05
to 5.7 0.04 g/liter), albumin (3.65 0.03 to 3.27 0.03 mg/dl),
calcium (8.8 0.05 to 8.2 0.03 mg!dl), magnesium (1.54 0.01
to 1.40 0.01 mg/dl), phosphorus (3.47 0.06 to 2.5 0.05
mg/dl), and uric acid (5.02 0.12 to 1.93 0.08 mgldl). There was
no significant variation in blood glucose (123.01 3.93 vs.
123.13 2.0 mg/dl) and total CO2 (23.5 0.21 vs. 23.1 0.22
mm/liter). However, there was a significant increase (P < 0.001)
from the baseline values for blood urea nitrogen (10.5 0.08 to
14.7 1.26 mg/dl) and total bilirubin (0.6 0.02 to 1.18 0.1
mg/dl). Hypomagnesemia less than 1 mg/dl was found in 37
patients (16%) with a mean in these patients of 0.86 0.02 mgldl.
During the chemotherapy substantial magnesium sulfate was
administered to keep the plasma magnesium concentration above
1.6 mg/dl. Similarly, potassium replacement was given to maintain
the plasma concentration above 3.2 mEq/liter if possible.
Changes in renal function after chemotherapy
An analysis of the entire 232 patient group revealed a signifi-
cant rise in serum creatinine (0.83 0.01 to 1.2 0.09 mg/dl, P <
0.001) and a decrease in calculated creatinine clearance (95 1.8
to 76 2.9 ml/min, P < 0.001) from day —7 to day 21. Renal
function was also analyzed three months after hematopoietic cell
support and showed a stable serum creatinine (1.12 0.07 mgldl)
and creatinine clearance (78.6 2.5 ml/min). The comparison of
renal function with the different protocols showed no differences,
except the patients treated with Taxol as compared to high dose
BCNU at four weeks post-chemotherapy had a lower creatinine
clearance (70.2 5.2 vs. 88.02 6.5 mI/mm, P < 0.02).
The changes in renal function were then analyzed based on the
severity of the dysfunction (Grades 0 to 3). During the hospital
course 102 patients (44%) had normal renal function (Grade 0).
81 patients (35%) had Grade 1 renal dysfunction, 42 patients
(18%) Grade 2 and 7 patients with Grade 3 renal dysfunction
were treated with dialysis (3%; Table 2). The 102 patients with
Grade 0 renal function had comparable ereatinine clearances
from baseline creatinine clearance to three months post-trans-
plantation, (87 vs. 85 ml/min, NS). Patients with Grade I renal
dysfunction had a rise in serum creatinine from 0.7 0.01 to 1.2
0.03 mg/dl (P < 0.001) and a fall in creatinine clearance from
102 3.4 mI/mm to 65 2.3 ml/min (P < 0.001) on day 11 0.08
post-hematopoietic cell support. The renal function improved
partially with the mean creatinine clearance increasing from 65±
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Table 2. Renal variables
Observation
time Parameters Grade 0 Grade 1 Grade 2/3
Baseline
Number of patients (%)
Serum creatinine mgldl
Creatinine clearance mi/mm
102 patients (44%)
0.8 0.01
87 2.3
81 patients (35%)
0.7 0.01
102 34a
49 patients (21%)
0.8 0.0297 44
Day of hematopoietic cell support Serum creatinine mg/di
Creatinine clearance mi/mm
0.9 0.01
83 2.2
1.04 0.04
77 3.2
1.25 0.08
71 4.0
Time of greatest average renal response Maximum serum creatinine mg/dl
Minimum creatinine clearance
mi/mm (time, days)
Proteinuria 100—300 mg/dl N(%)
Proteinuria 300 —500 mg/dl N(%)
0.95 0.01
80.5 2.2
33 (32)
6 (6)
1.2 0.03
65 2.3
31(38)
9 (11)
2.4 3.0
83 2.3
28 (57)
8 (16)
End of hospitalization Serum creatinine mg/di
Creatinine clearance mI/mm
(time, days)
0.83 0.01
92.3 2.6
22 0.7
0.95 0.02
81 3.3
25 0.8
1.8 0.2
54 3.5
28 1.4
3 Months post-transplant Serum creatinine mg/dl
Creatinine clearance mi/mm
0.89 0.03
85 4.01
0.99 0.03
83 4.0
1.62 0.27
64.5 4.65
P < 0.001 Grade 1 versus Grade 0
There was no difference between Grade 1 and Grade 2 baseline renal function. Values are mean SEM; values in parentheses are percentages.
2.3 to 81 3.3 ml/min (P < 0.00 1), 25 0.8 days after completion
of chemotherapy. However, at three months the creatinine clear-
ance was still at a lower level as compared to baseline creatinine
clearance (102 3.4 vs. 83 4.0 mI/mm, P < 0.001) in those
patients with Grade I renal dysfunction.
Patients with Grade 2/3 renal dysfunction (21%) had an eleva-
tion in serum creatinine of 1.8 0.2 mg/dl occurring on day 28
1.4; the maximum serum creatinine of 2.4 3.0 mg/dl, and a
minimum creatinine clearance of 38.0 2.3 mI/mm was measured
17 1.1 day after the baseline evaluation. The renal function, as
measured by calculated creatinine clearance, in this group was
64.5 4.7 mi/mm (P < 0.001) after three months. As with the
total patient group, a significant decline in renal function in both
Group 1 and 2/3 patients was present at the time of hematopoietic
cell support. The percentage decrements in calculated GFR are
plotted against the time course in Figure 1. Hypomagnesemia did
not correlate with renal outcomes.
Urinary protein concentration of 100 to 300 mg/dl was present
in a higher proportion of patients with Grade 2/3 renal dysfunc-
tion versus patients with normal (Grade 0) renal function (57% vs.
32%, P < 0.01) and patients with Grade 1 renal dysfunction (57%
Normal
renal
function
Parameters (Grade 0) Grade 1 Grade 2/3 P value
N (%) 102 (44) 81(35) 49(21)
Age years 43 0.7 43 0.7 44 1 NS
Baseline bilirubin 0.64 0.05 0.63 0.05 0.63 0.04 NS
mgldl
Baseline albumin 3.72 0.05 3.50 0.06 3.47 0.09 NS
mg/dl
Chemotherapy % 73,17,10 81.5,10,8.5 72,10,18 NS
regular, taxol,
mesna
Stage lI/Ill 34 (33) 23 (28) 20 (40) NS
Stage IV 65 (64) 58 (72) 29 (60) NS
Hypotension 18 (17) 10(12) 13 (26) <0.06
Sepsis 2 (2) 1(1.2) 5 (10) < 0.015
Amphotericin B 14 (14) 16(20) 7 (14) NS
Liver toxicity 5 (5) 5 (6) 16 (32.5) <0.0001
Hepatic VOD 2 (2) 2 (2.5) 7 (14) <0.01
Lung toxicity 11(11) 6(7.4) 12(24.5) <0.015
Neurotoxicity 10 (10) 6(7.5) 3 (7.5) NS
Mortality 4 (3.9) 3 (3.7) 9 (18.4) <0.002
(60 days post-
procedure)
vs. 38%, P < 0.02). Urinary protein concentration between 30(1
and 500 mg/liter was found in a higher frequency in patients with
Grade 1 and 2/3 versus patients with Grade 0 renal function (13%
vs. 6%, P < 0.03), but was the same frequency in patients with
Grade I and Grade 2/3 renal dysfunction (11% vs. 16%, NS).
Associated complications with Grade 2/3 renal dysfunction
As shown in Table 3 the Grade 2/3 renal dysfunction was
associated with a significantly higher mortality (18.4%) at 60 days
post-hematopoietic cell support than either the Grade 0 (3.9%) or
Grade 1 (3.7%) patients. Those Grade 2/3 patients who survived
three months post-hematopoietic cell support had significantly
Day—7 Day—i Day7 Day 14 Day2l
0
U-0
-25
—50
cEiJ
Table 3. Non-renal variables
Fig. 1. A significant decline in GFR in both Grade 1 and 2/3 patients is
present at the time of hematopoietic cell support on day —1 (P < 0.001).
After day —1, GFR is lower in patients with Grade 2/3 versus Grade 0/1
(P < 0.001). Symbols are: (•) Grade 0, N = 102; (•) Grade 1, N = 81;(A) Grade 2/3, N 49.
Values in parentheses are percentages.
P values are derived by analysis of variance (ANOVA) for continuous
variables and by chi square for frequencies and mortality.
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improved their renal function at that time as compared to their
earlier creatinine clearances (71 4.2 vs. 41 2.7 mI/mm, P <
0.001). There was no significant difference in mortality between
the Grade 0 versus Grade 1 patients. Differences in baseline renal
function could not explain the resultant differences in renal
dysfunction between the Grade 1 and Grade 2/3 patients (Table
2). The associated complications with the Grade 2/3 patients were
a significantly higher frequency of sepsis, hepatic toxicity and
hepatic VOD, and lung toxicity (Table 3). Of the 10 patients who
needed ventilatory support, all of them had Grade 2/3 renal
dysfunction; 33 of 49 patients (67%) with Grade 2/3 renal
dysfunction had fluid overload during the first week of chemo-
therapy. There was a 100% mortality in the 7 patients with hepatic
VOD; the diagnosis of hepatic VOD was confirmed at autopsy.
Only 2 of the 49 Grade 2/3 patients fulfilled the criteria of
hepatorenal syndrome. The frequency of hypotension was higher
in the Grade 2/3 patients but the difference did not reach
statistical significance. There was no evidence for differences in
duration and severity of hypotension between Grade 0 to 3.
Aminoglycosides were administered in all patients (Group 0 to 3)
and there was no difference in amphotericin B therapy between
the Grade 2/3 patients and the Grade 0/1 patients. The antibiotics
were never given during chemotherapy and virtually never begun
before day 0.
Using univariate analyses comparing patients with Grade 2/3
renal dysfunction versus Grade 0/1 demonstrated no statistical
differences in age, stage of breast cancer, baseline serum albumin
and serum bilirubin, type of chemotherapy protocol, hypotension,
role of aminoglycosides, amphotericin B, and neurotoxicity. How-
ever, significant differences were observed with the frequency of
sepsis (1.6% in patients with Grade 0/1 vs. 10.2% in patients with
Grade 2/3, P < 0.002), liver toxicity (5.5% in patients with Grade
O/l vs. 32.7% in patients with Grade 2/3, P < 0.0001) and lung
toxicity (9.3% in patients with Grade Oil vs. 24.5% in patients with
Grade 2/3, P < 0.002).
Age, stage of breast cancer, baseline bilirubin, baseline albu-
min, types of protocol, hypotension, use of nephrotoxic drugs
including aminoglycosides and amphotericin B and neurotoxicity
occurring during the hospital course were also not significantly
correlated with the Grade 2/3 patients with either a univariate or
multivariate analysis. However, liver toxicity (P < 0.0001), lung
toxicity (P < 0.015), and sepsis (P < 0.015) were significantly
associated with Grade 2/3 renal dysfunction in both univariate
(Table 3) and multivariate analyses (not shown). In the patients
with Grade 2/3 renal dysfunction 24% had lung toxicity, while
46.5% had either hepatic VOD (14%) or liver toxicity (32.5%).
Discussion
High dose chemotherapy and hematopoietic cell replacement
have been used to treat various diseases including aplastic anemia,
leukernias, multiple myeloma, non-Hodgkin and Hodgkin lym-
phoma, and solid tumors including ovarian and breast cancers.
The hematopoictic cell replacement involves either donor to
recipient marrow (allogeneic bone marrow transplant) or reinfu-
sion of the patient's own hematopoietic cells which have been
harvested from hone marrow or peripheral blood. Cytopheresis is
used to harvest progenitor cells from the patient's peripheral
blood. The hematopoietic cells are frozen and stored in the
autologous procedures for reinfusion after the high dose chemo-
therapy. With the allogeneic procedure the hematopoietic cells
are routinely harvested from donors and reinfused without cryo-
preservation.
Renal complications have been reported to be very prominent
in allogeneic bone marrow transplantation. In one large study of
272 patients [6], 241 were treated with allogeneic bone marrow
transplant and 31 patients with autologous bone marrow trans-
plantation. In this largely allogeneic study 53% of patients exhib-
ited severe renal insufficiency; specifically, 24% of patients re-
quired dialysis and 29% had at least a doubling of serum
creatinine without need for dialysis. This percentage of patients
with severe renal dysfunction is substantially greater than that
observed in the present study of patients receiving the autologous
procedure.
In allogeneic bone marrow transplant graft-versus-host reaction
and immunosuppressive agents including cyclosporine are present
[9, 10]; neither are involved in autologous bone marrow trans-
plantation. Since cyclosporine is known to be nephrotoxic, this is
one potential explanation for the substantial differences in renal
dysfunction which appears to result from allogeneic versus autol-
ogous hematopoietic cell support.
In the present study 232 women treated with high dose chemo-
therapy and autologous hematopoietic cell support for stage Il/Ill
(positive nodes) and stage IV (metastatic disease) were analyzed
in a retrospective manner. In this autologous study, only 3% or 7
patients underwent dialysis, whereas 18% or 42 patients had at
least a doubling of serum creatinine. Thus, although the compar-
ison is with a published report from another center, the 21% of
severe renal dysfunction in the present autologous study appears
to be substantially less than the observed 53% in a population of
predominantly allogeneic bone marrow transplant patients [6].
In the absence of graft-versus-host disease and no need for
cyclosporine treatment after autologous hematopoietic cell rein-
fusion, it could be hypothesized that renal dysfunction might
occur predominantly during the high dose chemotherapy period.
This was indeed the case in the present autologous study. Renal
toxicity of carmustine (BCNU) and cyclophosphamide (CPA) is
rare [11, 12]; in contrast, acute nephrotoxicity with cisplatin
(CDDP) has been observed in 30% of patients who receive doses
as high as 200 mg/rn2 even with adequate hydration using 3%
hypertonic saline [13]. In the present autologous study 130
patients (56%) observed a decrease of more than 25% in calcu-
lated creatinine clearance and 81 patients (35%) developed this
decrease in renal function during the first week after administra-
tion of 165 mg/rn2 of cisplatin with normal saline hydration over
72 hours. A recent study from our institution suggests that Taxol
is synergistic with the nephrotoxic effect of cisplatin [14]. In this
regard, the specific chernotherapeutic regimen overall was not
found to be a significant factor in the renal dysfunction, except
four weeks after cytoreduction therapy the patients who received
Taxol had a significantly lower (—22%) creatinine clearance than
those patients treated with BCNU. Taxol is a new antineoplastic
drug with toxic effects including hematological, cardiac and neu-
rotoxicity [15]. In this study 80% of the observed neurotoxicity
occurred in patients treated with Taxol.
In the present study after 60 days post-hematopoietic cell
support those patients who had no significant renal dysfunction
(Grade 0) did not have a different mortality than the patients with
modest renal dysfunction (Grade 1). At the same time, however,
those patients with severe renal dysfunction (Grade 2/3) had a
significantly increased mortality (18.4% vs. 3.9%, Grade 0 and
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3.7%, Grade 1, P < 0.002). There were no doubt other factors, in
addition to the potential nephrotoxic effects of cisplatin and
Taxol, which contributed to the renal dysfunction and higher
mortality in the Grade 2/3 patients. Although all patients received
aminoglycosides and thus these antibiotics could not alone explain
any differences in renal dysfunction (Grade 0 to 3), they could
have been a contributing factor in any decline in post-hematopoi-
etic cell reinfusion. Moreover, hypotension was more frequent in
the Grade 2/3 patients (26%) versus the Grade 1 (12%) and
Grade 0 (17%) patients (P < 0.06). Even though BCNU-related
hypotension lasted only 45 to 60 minutes and generally responded
to volume expansion, sepsis-related hypotension may have con-
tributed to the severe renal failure in the Grade 2/3 patients.
However, 10 of the 13 Grade 2/3 patients who had hypotension
exhibited this fall in blood pressure before the hematopoietic cell
support or neutropenia.
There was a highly significant correlation, both by univariate
and multivariate analysis, between renal dysfunction and sepsis.
The patients with Grade 2/3 renal dysfunction also had a 32.5%
incidence of hepatic complications including liver toxicity (18.5%)
and hepatic VOD (14%). Seven of the 11 patients with hepatic
VOD exhibited Grade 2/3 renal dysfunction and the mortality rate
was 100% in these seven patients. In a previous series of patients
with allogeneic bone marrow transplant, hepatic VOD was re-
ported to occur in 54% of all patients [16]. In contrast, hepatic
VOD occurred in only 4.7% of all patients (11 of 232) in the
present study. In contrast to reports in patients treated with
allogeneic bone marrow transplant, our patients treated with
autologous hematopoietic cell support did not exhibit hepatorenal
syndrome as a predominant cause of acute renal failure. In fact,
only 2 of the 49 in the Group 2/3 patients fulfilled the criteria for
the hepatorenal syndrome. In the study by Zager et al [6] 90% of
patients treated with allogeneic bone marrow transplant who
developed acute renal failure had hepatorenal syndrome.
Evidence of fluid overload with pulmonary edema and pleural
effusions was present in two-thirds of the 49 patients with Grade
2/3 renal dysfunction, no doubt because these patients received
larger amounts of fluid to maintain urine flows greater than 250
mI/mm during the high dose chemotherapy. Pulmonary toxicity,
which has been previously reported in this setting [17], was also
more frequent in these Grade 2/3 patients as compared to Grade
0/1 patients (9.3% vs. 24.5%, P < 0.002). Thirty-three of 49 (67%)
of Grade 2/3 patients were also fluid overloaded during the period
of chemotherapy.
In summary, autologous hematopoietic cell support for treat-
ment of breast cancer is associated with a lower frequency of
severe renal dysfunction, hepatorenal syndrome and hepatic
VOD than reported results with allogeneic bone marrow trans-
plant. Severe renal dysfunction (21% of all patients were Group
2/3) was associated hypotension, sepsis, liver and lung complica-
tions as well as a higher mortality than in patients with normal or
mild renal dysfunction (79% of all patients were Group 0/1)
associated with the same autologous procedure. The chemothera-
peutic agents, particularly cisplatin and Taxol, on the background
of uniform aminoglycoside therapy, hypotension and sepsis, play
an important role in mediating the severe renal dysfunction
observed in women with node positive and metastatic breast
cancer treated with autologous hematopoietic cell support.
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